For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 million GAAP net loss of$81.6 million Adjusted EBITDA of $29.5 million GAAP and adjusted diluted earnings (loss) per share of$(0.91) and $(0.04), respectively Book-to-bill ratio of 1.11x, resulting in >1.2x book-to-bill for the trailing nine months Planned divestiture of assets relating to the Endpoint Clinical and Patient Access businesses on track DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) ...